The efficacy of ixazomib for the treatment of R/R myeloma



Published
In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, briefly discusses the efficacy of ixazomib, an oral proteasome inhibitor, for the treatment of relapsed/refractory (R/R) myeloma. Prof. Jackson also comments on the importance of this efficacious agent during the COVID-19 pandemic. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Category
Health
Be the first to comment